Share-based Payment Arrangement, Expense of BICYCLE THERAPEUTICS PLC from 31 Dec 2017 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
BICYCLE THERAPEUTICS PLC quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2017 to 30 Sep 2025.
  • BICYCLE THERAPEUTICS PLC Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $8,771,000, a 4.7% decline year-over-year.
  • BICYCLE THERAPEUTICS PLC Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $38,144,000, a 7.3% increase year-over-year.
  • BICYCLE THERAPEUTICS PLC annual Share-based Payment Arrangement, Expense for 2024 was $38,081,000, a 17% increase from 2023.
  • BICYCLE THERAPEUTICS PLC annual Share-based Payment Arrangement, Expense for 2023 was $32,477,000, a 21% increase from 2022.
  • BICYCLE THERAPEUTICS PLC annual Share-based Payment Arrangement, Expense for 2022 was $26,779,000, a 122% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

BICYCLE THERAPEUTICS PLC Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $38,144,000 $8,771,000 -$431,000 -4.7% 01 Jul 2025 30 Sep 2025 10-Q 30 Oct 2025 2025 Q3
Q2 2025 $38,575,000 $9,435,000 +$171,000 +1.8% 01 Apr 2025 30 Jun 2025 10-Q 08 Aug 2025 2025 Q2
Q1 2025 $38,404,000 $9,605,000 +$323,000 +3.5% 01 Jan 2025 31 Mar 2025 10-Q 01 May 2025 2025 Q1
Q4 2024 $38,081,000 $10,333,000 +$2,521,000 +32% 01 Oct 2024 31 Dec 2024 10-K 25 Feb 2025 2024 FY
Q3 2024 $35,560,000 $9,202,000 +$1,772,000 +24% 01 Jul 2024 30 Sep 2024 10-Q 30 Oct 2025 2025 Q3
Q2 2024 $33,788,000 $9,264,000 +$1,071,000 +13% 01 Apr 2024 30 Jun 2024 10-Q 08 Aug 2025 2025 Q2
Q1 2024 $32,717,000 $9,282,000 +$240,000 +2.7% 01 Jan 2024 31 Mar 2024 10-Q 01 May 2025 2025 Q1
Q4 2023 $32,477,000 $7,812,000 +$2,272,000 +41% 01 Oct 2023 31 Dec 2023 10-K 25 Feb 2025 2024 FY
Q3 2023 $30,205,000 $7,430,000 +$2,062,000 +38% 01 Jul 2023 30 Sep 2023 10-Q 31 Oct 2024 2024 Q3
Q2 2023 $28,143,000 $8,193,000 +$2,520,000 +44% 01 Apr 2023 30 Jun 2023 10-Q 06 Aug 2024 2024 Q2
Q1 2023 $25,623,000 $9,042,000 -$1,156,000 -11% 01 Jan 2023 31 Mar 2023 10-Q 02 May 2024 2024 Q1
Q4 2022 $26,779,000 $5,540,000 +$2,541,000 +85% 01 Oct 2022 31 Dec 2022 10-K 25 Feb 2025 2024 FY
Q3 2022 $24,238,000 $5,368,000 +$2,680,000 +100% 01 Jul 2022 30 Sep 2022 10-Q 02 Nov 2023 2023 Q3
Q2 2022 $21,558,000 $5,673,000 +$3,098,000 +120% 01 Apr 2022 30 Jun 2022 10-Q 03 Aug 2023 2023 Q2
Q1 2022 $18,460,000 $10,198,000 +$6,377,000 +167% 01 Jan 2022 31 Mar 2022 10-Q 04 May 2023 2023 Q1
Q4 2021 $12,083,000 $2,999,000 +$1,435,000 +92% 01 Oct 2021 31 Dec 2021 10-K 20 Feb 2024 2023 FY
Q3 2021 $10,648,000 $2,688,000 +$1,178,000 +78% 01 Jul 2021 30 Sep 2021 10-Q 03 Nov 2022 2022 Q3
Q2 2021 $9,470,000 $2,575,000 +$1,256,000 +95% 01 Apr 2021 30 Jun 2021 10-Q 04 Aug 2022 2022 Q2
Q1 2021 $8,214,000 $3,821,000 +$1,700,000 +80% 01 Jan 2021 31 Mar 2021 10-Q 05 May 2022 2022 Q1
Q4 2020 $6,514,000 $1,564,000 +$481,000 +44% 01 Oct 2020 31 Dec 2020 10-K 28 Feb 2023 2022 FY
Q3 2020 $6,033,000 $1,510,000 +$691,000 +84% 01 Jul 2020 30 Sep 2020 10-Q 04 Nov 2021 2021 Q3
Q2 2020 $5,342,000 $1,319,000 +$414,000 +46% 01 Apr 2020 30 Jun 2020 10-Q 05 Aug 2021 2021 Q2
Q1 2020 $4,928,000 $2,121,000 +$1,845,000 +668% 01 Jan 2020 31 Mar 2020 10-Q 06 May 2021 2021 Q1
Q4 2019 $3,083,000 $1,083,000 01 Oct 2019 31 Dec 2019 10-K 01 Mar 2022 2021 FY
Q3 2019 $819,000 +$589,000 +256% 01 Jul 2019 30 Sep 2019 10-Q 05 Nov 2020 2020 Q3
Q2 2019 $905,000 +$570,000 +170% 01 Apr 2019 30 Jun 2019 10-Q 05 Aug 2020 2020 Q2
Q1 2019 $276,000 01 Jan 2019 31 Mar 2019 10-Q 07 May 2020 2020 Q1
Q3 2018 $230,000 01 Jul 2018 30 Sep 2018 10-Q 07 Nov 2019 2019 Q3
Q2 2018 $335,000 01 Apr 2018 30 Jun 2018 10-Q 08 Aug 2019 2019 Q2

BICYCLE THERAPEUTICS PLC Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $38,081,000 +$5,604,000 +17% 01 Jan 2024 31 Dec 2024 10-K 25 Feb 2025 2024 FY
2023 $32,477,000 +$5,698,000 +21% 01 Jan 2023 31 Dec 2023 10-K 25 Feb 2025 2024 FY
2022 $26,779,000 +$14,696,000 +122% 01 Jan 2022 31 Dec 2022 10-K 25 Feb 2025 2024 FY
2021 $12,083,000 +$5,569,000 +85% 01 Jan 2021 31 Dec 2021 10-K 20 Feb 2024 2023 FY
2020 $6,514,000 +$3,431,000 +111% 01 Jan 2020 31 Dec 2020 10-K 28 Feb 2023 2022 FY
2019 $3,083,000 +$2,060,000 +201% 01 Jan 2019 31 Dec 2019 10-K 01 Mar 2022 2021 FY
2018 $1,023,000 +$508,000 +99% 01 Jan 2018 31 Dec 2018 10-K 11 Mar 2021 2020 FY
2017 $515,000 01 Jan 2017 31 Dec 2017 10-K 10 Mar 2020 2019 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.